Table 3.
Main Ongoing Clinical Trials of Anti-Tim-3 Agents Combined with ICIs
| Clinical Trial | Cancer Type | Treatment Line | Anti-Tim-3 Agent | Immunotherapy | Phase |
|---|---|---|---|---|---|
| NCT03099109 | Advanced solid tumors | ≥2 | LY3321367 | LY3300054 (anti-PD-L1 mAb) | I |
| NCT03307785 | Advanced solid tumors | ≥2 | TSR-022 | TSR-042 (anti-PD-L1 mAb) | I |
| NCT03311412 | Advanced solid tumors and/or lymphomas | ≥2 | Sym023 | Sym021 (anti-PD-1 mAb) | I |
| NCT02817633 (AMBER) Part 1 Part2 cohort B (NSCLC) | Advanced solid tumors | ≥2 | TSR-022 | Nivolumab or TSR-042 (anti-PD-1 mAb) | I |
| NCT03708328 | Advanced solid tumors | ≥2 | RO7121661 (anti-PD-1/TIM-3 bispecific mAb) | – | I |
| NCT03744468 | Advanced solid tumors | ≥2 | BGB-A425 | Tislelizumab (anti-PD-1 mAb) | I/II |
Abbreviations: NSCLC, non-small cell lung cancer; mAb, monoclonal antibody.